Merck Uses Phosphoproteomics to Identify Potential Biomarkers for Cancer Drug Development | GenomeWeb

By Adam Bonislawski

A research team led by Merck scientists has taken what could represent a first step toward using phosphoproteins as biomarkers for cancer drug development.

Examining prostate cancer cells treated with three investigational drugs targeting the phosphatidylinositol 3-kinase, or PI3K, signaling pathway, the researchers identified 375 nonredundant serine-threonine phosphopeptides within the pathway, of which 71 were regulated by at least one drug and 11 were regulated by all three drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.